We are live on
!
Find out more
NMC
NEA Management Company Portfolio holdings
AUM
$1.76B
1-Year Est. Return
223.33%
This Fund
S&P 500
This Quarter
Est. Return
+5.76%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$1.29B
AUM Growth
-$15.1M
(-1.2%)
Cap. Flow
+$17.3M
Cap. Flow
% of AUM
1.33%
Top 10 Holdings %
Top 10 Hldgs %
69%
Holding
47
New
3
Increased
3
Reduced
2
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sagimet Biosciences
SGMT
|
+$51.3M |
| 2 |
Gossamer Bio
GOSS
|
+$14.1M |
| 3 |
Geron
GERN
|
+$3.88M |
| 4 |
Savara
SVRA
|
+$1.19M |
| 5 |
IMA
ImageneBio Inc
IMA
|
+$911K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BGRY
Berkshire Grey, Inc. Class A Common Stock
BGRY
|
+$53.8M |
| 2 |
Acrivon Therapeutics
ACRV
|
+$594K |
| 3 |
EAR
Eargo, Inc. Common Stock
EAR
|
+$404K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 74.22% |
| 2 | Consumer Staples | 18.57% |
| 3 | Technology | 3.84% |
| 4 | Industrials | 2.91% |
| 5 | Communication Services | 0.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Coursera
COUR
$1.74B
| $240M | 18.57% |
12,867,769
| – | – |
|
|
ACLX
2
DELISTED
Arcellx
ACLX
| $134M | 10.38% |
3,745,262
| – | – |
|
|
3
Savara
SVRA
$1.08B
| $92.5M | 7.14% |
24,471,264
+333,333
| +1% | +$1.19M |
|
|
VRNA
4
DELISTED
Verona Pharma
VRNA
| $91M | 7.03% |
5,108,563
| – | – |
|
5
CRISPR Therapeutics
CRSP
$4.65B
| $72.1M | 5.57% |
1,587,854
| – | – |
|
6
Mirum Pharmaceuticals
MIRM
$6.67B
| $69.1M | 5.34% |
2,186,243
| – | – |
|
7
Rhythm Pharmaceuticals
RYTM
$7.36B
| $66.7M | 5.15% |
2,909,956
| – | – |
|
|
8
Geron
GERN
$917M
| $48.3M | 3.73% |
22,776,409
+1,428,571
| +7% | +$3.88M |
|
9
NextNav
NN
$1.78B
| $42.1M | 3.25% |
8,189,156
| – | – |
|
10
Monte Rosa Therapeutics
GLUE
$1.85B
| $36.8M | 2.85% |
7,692,298
| – | – |
|
|
OKUR
11
OnKure Therapeutics
OKUR
$160M
| $36.4M | 2.81% |
478,549
| – | – |
|
12
CVRx
CVRX
$133M
| $36M | 2.78% |
2,370,542
| – | – |
|
13
Celcuity
CELC
$3.92B
| $31.8M | 2.46% |
1,250,001
| – | – |
|
14
Aurinia Pharmaceuticals
AUPH
$1.92B
| $30.8M | 2.38% |
3,969,834
| – | – |
|
|
15
Sagimet Biosciences
SGMT
$439M
| $27.1M | 2.09% |
+3,850,275
| New | +$51.3M |
|
16
Trevi Therapeutics
TRVI
$2.54B
| $24.8M | 1.91% |
11,370,376
| – | – |
|
|
DM
17
DELISTED
Desktop Metal, Inc.
DM
| $21M | 1.62% |
1,440,759
| – | – |
|
18
X4 Pharmaceuticals
XFOR
$374M
| $16.3M | 1.26% |
499,560
| – | – |
|
|
NEUE
19
DELISTED
NeueHealth
NEUE
| $16.3M | 1.26% |
2,726,917
| – | – |
|
|
ZFOX
20
DELISTED
ZeroFox Holdings, Inc. Common Stock
ZFOX
| $15.9M | 1.23% |
18,068,513
| – | – |
|
|
ALLK
21
DELISTED
Allakos
ALLK
| $14M | 1.08% |
6,147,260
| – | – |
|
|
ADAP
22
DELISTED
Adaptimmune Therapeutics
ADAP
| $13.3M | 1.03% |
17,079,778
| – | – |
|
|
23
Gossamer Bio
GOSS
$96.6M
| $13.1M | 1.01% |
15,727,942
+12,260,536
| +354% | +$14.1M |
|
24
Black Diamond Therapeutics
BDTX
$95.7M
| $12.8M | 0.99% |
4,448,757
| – | – |
|
25
Phathom Pharmaceuticals
PHAT
$928M
| $12.2M | 0.95% |
1,276,595
| – | – |
|
Similar funds
NM
SLF
CCIA
SW
CGH
PWP
CIP
KOCAA
NEA Management Company's Q3 2023 Portfolio in Review
As of Q3 2023, NEA Management Company held 47 positions worth $1.29B, down 1.2% from $1.31B the previous quarter. Its ten largest holdings account for 69% of the portfolio.
NEA Management Company's Q3 2023 filing shows 3 new, 3 increased, 2 reduced and 1 closed positions. Its largest new stake was Sagimet Biosciences: 3,850,275 shares worth $27.1M. The largest sale was Berkshire Grey, Inc. Class A Common Stock, an estimated $53.8M.
By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 77% a quarter earlier, followed by Consumer Staples and Technology.
- NEA Management Company's largest Q3 2023 buy was Sagimet Biosciences: 3,850,275 shares worth $27.1M.
- NEA Management Company added most to Gossamer Bio in Q3 2023, an estimated $14.1M increase.
- NEA Management Company's biggest Q3 2023 reduction was Acrivon Therapeutics, cutting an estimated $594K.
- NEA Management Company fully exited Berkshire Grey, Inc. Class A Common Stock in Q3 2023, selling an estimated $53.8M.
- NEA Management Company's ten largest holdings make up 69% of its $1.29B portfolio in Q3 2023.
- NEA Management Company opened 3 new positions and closed 1 in Q3 2023.
- NEA Management Company's portfolio value fell 1.2% quarter-over-quarter to $1.29B.
Based on NEA Management Company's 13F filing for Q3 2023, filed 14 Nov 2023.